<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543490</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-305-001</org_study_id>
    <nct_id>NCT01543490</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects</brief_title>
  <acronym>ISV-305</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSite Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSite Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305
      (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active,
      symptomatic Blepharitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of total clinical sign and symptom score</measure>
    <time_frame>Day 15</time_frame>
    <description>The primary efficacy endpoint for the comparison of ISV-305 and Vehicle is the reduction of Day 1 total clinical sign and symptom score by at least 2 units at Day 15 with no worsening of any sign or symptom</description>
  </primary_outcome>
  <other_outcome>
    <measure>Additional Efficacy Endpoints: Patient-reported outcome questionnaire (PRO)</measure>
    <time_frame>Days 1, 15, 29</time_frame>
    <description>Mean scores and mean score changes for each domain of the PRO</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Active, Symptomatic Blepharitis</condition>
  <arm_group>
    <arm_group_label>ISV-305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-305</intervention_name>
    <description>Dexamethasone in DuraSite® 2 twice daily for 2 weeks</description>
    <arm_group_label>ISV-305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo twice daily for 2 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 1 years of age and have a clinical diagnosis of active, symptomatic
             blepharitis

          -  Signature of the subject or parent(s) or legally authorized representative on the
             Informed Consent Form, and when appropriate the minor's assent in accordance with
             local regulations

          -  Are willing and able to follow all instructions and attend all study visits (this
             applies to parent or caregiver for subjects too young to self-apply investigational
             product)

          -  Are willing to avoid disallowed medication for the duration of the study

          -  If female is of childbearing potential, agree to and submit a urine sample for
             pregnancy testing (prior to enrollment and at the end of the study) and use effective
             contraception for the duration of the study

          -  Male subjects whose female partners are not post-menopausal must agree to one of the
             following: 1) completely abstain from sexual intercourse, 2) use a barrier method
             (condoms) with spermicide during sexual intercourse for the duration of the study, 3)
             provide documentation for having had a vasectomy (with documented infertility)

          -  Additional inclusion criteria also apply

        Exclusion Criteria:

          -  Have known sensitivity or poor tolerance to any component of the study drugs

          -  Have had eyelid surgery in the study eye within twelve (12) months prior to Visit 1 or
             plan to have eyelid surgery during the study

          -  Have an acute ocular infection (bacterial, viral or fungal) or active ocular
             inflammation other than blepharitis in the study eye

          -  Have used topical medications on the eyelids or topical ophthalmic corticosteroid
             medications or systemic use of a corticosteroid mediation within 14 days prior to
             dosing and/or plan to use them throughout the duration of the study

          -  Be currently pregnant, nursing, or planning a pregnancy; or be a woman who has a
             positive urine pregnancy test

          -  Have prior (within 30 days prior to dosing) or anticipated concurrent use of an
             investigational drug or device

          -  Have a condition or a situation which, in the investigator's opinion, may put the
             subject at increased risk, confound study data, or interfere significantly with the
             subject's study participation

          -  Additional exclusion criteria also apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charlotte Baenziger</last_name>
    <phone>510-747-1219</phone>
    <email>charlotte.baenziger@sunpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

